# Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

Study · id `cardio:ct-nct07102511` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07102511](<https://clinicaltrials.gov/study/NCT07102511>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07102511

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 150 participants.

## Technical summary

Registry record NCT07102511. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-20 (actual); primary completion 2028-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT07102511, source copy `cardio:ctgov-nct07102511-2026-07-28`, retrieved 2026-10-31)
- Started: 2026-07-20 (actual) (ClinicalTrials.gov record NCT07102511, source copy `cardio:ctgov-nct07102511-2026-07-28`, retrieved 2026-10-31)
- Primary completion: 2028-07-31 (anticipated) (ClinicalTrials.gov record NCT07102511, source copy `cardio:ctgov-nct07102511-2026-07-28`, retrieved 2026-10-31)
- Completion: 2028-11-30 (anticipated) (ClinicalTrials.gov record NCT07102511, source copy `cardio:ctgov-nct07102511-2026-07-28`, retrieved 2026-10-31)
- Countries: United States; Israel; New Zealand; Norway; South Africa; Türkiye (ClinicalTrials.gov record NCT07102511, source copy `cardio:ctgov-nct07102511-2026-07-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07102511-2026-07-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
- Acronym: LIBerateKids
- Condition: Familial Hypercholesterolemia - Heterozygous
- Intervention (Biological): lerodalcibep 300 mg Monthly SC
- Lead sponsor: LIB Therapeutics LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: LIB Therapeutics LLC (`cardio:org-lib-therapeutics-llc`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

## Provenance

Content hash: f9a060fe26ed44b7aaa1b36084481fd6802f2b9f13ce2329a5f0c061896389f6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
